NATCO Pharma launches lenalidomide 2.5mg and 20mg in US
NATCO Pharma said that it has launched additional strengths for the generic version of Revlimid (lenalidomide capsules), in the strengths of 2.5mg and 20mg in ... Read More
Dr Reddy’s Labs announces limited volume US launch of Lenalidomide Capsules
Dr Reddy’s Laboratories said that it has launched two of six strengths of cancer medication Lenalidomide Capsules, a generic of Revlimid, which has been approved ... Read More
Natco Pharma launches PrNAT-LENALIDOMIDE Capsules in Canada
Natco Pharma Limited has announced the Canadian launch of PrNAT-LENALIDOMIDE Capsules, a generic version of Celgene Corporation’s cancer drug Revlimid. The launch was announced earlier ... Read More
Zydus Cadila gets FDA approval for Revlimid generic Lenalidomide Capsules
Zydus Cadila said that the US Food and Drug Administration (FDA) has granted it tentative approval for Lenalidomide Capsules, a generic version of Celgene Corporation’s ... Read More
Sun Pharma to settle patent litigation with Celgene for generic Revlimid
Sun Pharmaceutical Industries (Sun Pharma) along with one of its fully-owned subsidiaries has reached an agreement with Celgene, a fully-owned subsidiary of Bristol Myers Squibb, ... Read More
Natco Pharma gets FDA approval for Lenalidomide Capsules
Natco Pharma has secured the final approval from the US Food and Drug Administration (FDA) of its abbreviated new drug application (ANDA) for Lenalidomide Capsules, ... Read More
Bristol-Myers Squibb to acquire Celgene in $74bn pharma megadeal
Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately $74 billion. This acquisition will merge two ... Read More